AFP and hepatocellular carcinoma: Stratified by HCC recurrence risk after curative treatment, serum AFP or combined with AFP-L3, DCP and routine abdominal ultrasound, or liver multiparametric MRI, CT dynamic contrast-enhanced imaging are routinely used to surveil HCC recurrence once every 1–2 months for first 3 months, once every 3 months from 3 months to 2 years and once every 6 months thereafter.